Our roots are in one of America’s great entrepreneurial success stories. Fidelity Investments was founded in 1946 and grew from a single mutual fund into one of the largest asset management firms in the world, with over $2 trillion in assets under management. For the last forty years, our venture capital group has had the privilege of backing other great entrepreneurs as they built ground-breaking companies in technology and life sciences, including Atari, MCI, ROLM Corp., Alibaba, Ironwood Pharmaceuticals, and Ultragenyx.

Today our funds are larger and more global, but our teams are still small and local. We stay true to our entrepreneurial roots. In the US and Europe, we are F-Prime Capital investing in healthcare (formerly Fidelity Biosciences) and in technology (formerly part of Devonshire Investors). In other geographies, our sister fund is called Eight Roads (formerly Fidelity Growth Partners), with investment teams in London, Shanghai, Beijing, Hong Kong, Tokyo, and Mumbai. Together we bring a world of insight, domain expertise and relationships to support our entrepreneurs. Without the pressure of fundraising from outside investors, we focus all of our time finding and helping great entrepreneurs build important companies.

Wellframe

Kensho

Cytek Biosciences

Denali Therapeutics

Even Financial

Beam Therapeutics

Blueprint Medicines

Checkmate Pharmaceuticals

Iora Health

Farapulse

Ivenix

Sana Biotechnology

Coherus Biosciences

Acacia Pharma

Adagene

Adaptimmune

Apellis Pharmaceuticals

Artemis Health

Avidity Biosciences

Structure Therapeutics

Tempest Therapeutics

Toast

TradeBlock

Verve Therapeutics

ViewRay

Orchard Therapeutics

OZiva

PatientPing

Precision BioSciences

Prime Medicine

Recurly

REGENXBIO

F-Prime Capital

It was a full house yesterday at the Broad Institute of MIT and Harvard for the 2024 #Science2Startup symposium. Thank you to everyone who joined us for a day filled with insightful presentations, engaging panel discussions, and valuable networking opportunities centered around the future of the #biotech industry.
 
Boston's vibrant #lifesciences ecosystem makes it an unparalleled hub for innovation, and we are thrilled to continue our efforts to drive forward scientific breakthroughs and entrepreneurial ventures.

On the F-Prime Capital team, we'd specifically like to thank Jessica Alston and Stacie Weninger for participating as Advisors, Chong Xu for moderating, and Alexander Munoz, MD, Raj Basak, Davina Magargal, Allison (Gosman) Kanter and Emily Tynan for their work on the Steering Committee.
 
Stay tuned for details on next year's event!
 
Atlas Venture │ 5AM Ventures │ Osage University Partners (OUP) │ RA Capital Management │ MassBio │ Colliers │ Deloitte │ Evotec │ Goodwin │ Pliancy │ Silicon Valley Bank

Thank you to our 2024 #Science2Startup fireside chat speaker, David R. Liu, Ph.D., and moderator, Deborah Palestrant, Ph.D., M.B.A., for kicking off this year's event.

During their discussion, Liu spoke about his professional and academic journey, how he began working with #VentureCapital organizations, how he stays committed to science and patient care, and more.

"Problem selection, still very very important. Trust, give anybody who wants to work with you, the opportunity to work with you, if possible. But developing a network of people you trust is really important for translation. And ultimately, for this audience, where I noticed everything was a therapeutics company, keep patient interest upfront. That's such an important guiding star and you can virtually never go wrong if you just keep patient interest upfront, it will help everything. And you also, coincidentally, build the most value if you end up keeping patient interest upfront because all of this is not just a marathon, it's an ultramarathon, so not letting the short-term eccentricities of what an investor did or didn't do, how the value of your stock, if it's publicly traded, is changing or not; don't let that bother you. In the end, if you are actually helping people, if you keep patient interest upfront, you will generate enough value that everybody will be happy that way, and more importantly, in the end, I don't think you're going to care that much about how many digits are in your bank account, which is not even associated with physical money anymore, but I think people will remember you for the impact you had on the lives of patients who maybe didn't have a treatment otherwise."


Atlas Venture │ 5AM Ventures │ Osage University Partners (OUP) │ RA Capital Management │ MassBio │ Colliers │ Deloitte │ Evotec │ Goodwin │ Pliancy │ Silicon Valley Bank │ Broad Institute of MIT and Harvard
#biotech #pharma #startup

Congratulations to Jeff Walsh, Melissa Bonner, Ph.D., and Lisa McGrath and the rest of the Nvelop Therapeutics team on your formal launch to develop the next generation of genetic medicines. This launch represents a significant step forward for the development of future genetic medicines for a wide range of diseases thanks to their approach of enabling highly efficient and cell-specific deliveries to a broad range of therapeutic cargoes.

“The field of genetic medicine is significantly limited by the challenge of efficiently delivering therapeutic cargoes to many types of target cells in vivo,” said Jeff Walsh, Nvelop’s CEO. “With the combination of best-in-class technologies, scientific co-founders with a deep track record in cell and gene therapy, and a team that has pioneered the development of some of the first approved therapies in the field, Nvelop is uniquely positioned to unlock the promise of genetic medicines.”

Learn more: https://bit.ly/4cR7VcI 

Jessica Alston #GeneticMedicine #healthcare

The 2024 #Science2Startup symposium is this Wednesday! After exciting discussions and powerful networking, 8 researchers will present their ideas and interact with leading investors and executives in the Boston #biotech hub. 

Thank you to our event co-hosts Atlas Venture, 5AM Ventures, Osage University Partners (OUP), RA Capital Management, and MassBio. 

Make sure to follow along for updates!

Join us for Demo Day[s] 10 on Thursday, April 11, to hear venture investor David Jegen, Fintech Sandbox Co-Founder and Managing Partner of F-Prime Capital, discuss the digitization of private markets, an investment theme he finds particularly interesting right now. https://bit.ly/48mXOc2

IPhone / Mobile Compatible

Viewport Meta

Domain Not Resolving

Euro

Google Tag Manager

Apple Mobile Web Clips Icon

HSTS

Google Analytics

WordPress

Global Site Tag

Chief Operating Officer

Mary Bevelock

Vice President of Finance

Debbie Costello

Debbie Griffin

Vice President Human Resources

Sean Quimby

Finance and Administration

Andrew Bognanni

Principal

Benjamin Gorman

Brian Yordy

Senior Director of Finance

Cathy Wong

Vice President of Marketing

Davina Magargal

Grace Byrne

Stephen Knight

President & Managing Partner

Ben Auspitz

Partner

David Jegen

Managing Partner

Robert Weisskoff

Jon Lim

Gaurav Tuli

Sanjay Aggarwal

Venture Partner

Ben Gorman

Sana Biotechnology is a developer of engineered cells intended to be used as medicine for patients.

Avidity Biosciences is a biotechnology company that develops oligonucleotide-based therapies for its patients.

Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.

Prime Medicine operates as a biotechnology company that delivers the promise of gene editing using Prime Editing.

Cytek Biosciences is a manufacturer and supplier of flow cytometry products and services.

Subscription billing management SaaS platform powering 2,000+ brands including Sling TV, BarkBox, Asana, FabFitFun, Cinemark & Twitch

Tempest Therapeutics is a biotechnology company that focuses on small molecule therapeutics that modulate anti-tumor pathways.

Bicara Therapeutics develops dual-action cancer therapies, combining targeted treatments with tumor modulators for enhanced impact.

Verve Therapeutics is a genetic medicine firm that is developing treatments for cardiovascular disease.

Turnstone Biologics is a privately-held clinical stage biotech company.

Seed Stage Investors with Investments in China

Investors Active in San Francisco Bay Area (Top 10K)

Seed Stage Investors with Investments in Greater Philadelphia Area

Early Stage Venture Investors with Investments in Detroit, Michigan

F-Prime's roots are in one of America’s great entrepreneurial success stories. Fidelity Investments was founded in 1946 and grew from a single mutual fund into one of the largest asset management firms in the world, with over $2 trillion in assets under management. For the last forty years, this venture capital group has had the privilege of backing other great entrepreneurs as they built ground-breaking companies in technology and life sciences, including Atari, MCI, ROLM Corp., Alibaba, Ironwood Pharmaceuticals, and Ultragenyx.

Today, F-Prime's funds are larger and more global, but its teams are still small and local. F-Prime stays true to its entrepreneurial roots. In the US and Europe, F-Prime Capital Partners is investing in healthcare (formerly Fidelity Biosciences) and in technology (formerly part of Devonshire Investors). In other geographies, its sister fund is called Eight Roads (formerly Fidelity Growth Partners), with investment teams in London, Shanghai, Beijing, Hong Kong, Tokyo, and Mumbai. 

Together F-Prime brings a world of insight, domain expertise and relationships to support entrepreneurs. Without the pressure of fundraising from outside investors, F-Prime Capital Partners focuses all of its time finding and helping great entrepreneurs build important companies.

Cambridge

Massachusetts

United States

North America

AvenCell: Clinical-Stage Cell Therapy Company Raises $112 Million (Series B)

Shift Bioscience: $16 Million (Seed) Raised To Use GenAI For Reversing Aging Processes

India

Asia

United Kingdom

Europe

The Netherlands

Nepal

HTML5

jQuery

F5 NGINX

Wordpress

Apache Server

DigiCert

Google Maps API

Google Drive

Adobe Fonts

KKR is a global investment firm that manages multiple alternative asset classes, including private equity, energy, infrastructure, real estate, credit, and, through its strategic partners, hedge funds.

TPG is a leading global alternative asset firm founded in 1992 with approximately $83 billion of assets under management and offices in Austin, Beijing, Boston, Dallas, Fort Worth, Hong Kong, Houston, London, Luxembourg, Melbourne, Moscow, Mumbai, New York, San Francisco, Seoul, and Singapore.

CVC Capital Partners is a leading global private equity and investment advisory firm. Founded in 1981, CVC today has a network of 24 offices and over 500 employees throughout Europe, Asia, and the Americas.

Bain Capital Ventures is the venture capital arm of Bain Capital, and the firm's partners have been investing in early-stage software, hardware, and technology companies since 1984.

Bain Capital Ventures

Warburg Pincus is a leading global private equity firm focused on growth investing. The firm has more than $58 billion in private equity assets under management.

Warburg Pincus

F Prime Capital is a venture capital firm that invests in technology and financial services companies. The firm focuses on early-stage investments, partnering with entrepreneurs to build significant, sustainable businesses.

news impact assignment basic	general
public peers	general	May 10, 2024 11:35 PM	e3bd42d4
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 18, 2024 2:12 PM	b97651ae
crunchbase profile	general	Nov 19, 2024 2:01 AM	d75afff5
li profile	general	May 10, 2024 11:35 PM	74818591
translate crunchbase fundingrounds	general	Nov 19, 2024 2:33 AM	1113a338
peers	general
news basic	general
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:FPRIMECAPITAL

F Prime Capital